Crossmark

Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany

Crossref DOI link: https://doi.org/10.1007/s10198-017-0953-z

Published Online: 2018-01-23

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pöllinger, Bernadette

Schmidt, Wolfgang

Seiffert, Anna

Imhoff, Heidi

Emmert, Martin
Funding

Funding for this research was provided by:

MSD Haar, Germany
License Information

Text and Data Mining valid from 2018-01-23
More Information

Article History

Received: 10 December 2016

Accepted: 21 December 2017

First Online: 23 January 2018